Načítá se...
SA17. Response to Treatment With Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia
Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder resulting from exposure to dopamine receptor-blocking agents (DRBAs), such as antipsychotics. Valbenazine is a novel and highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that is being...
Uloženo v:
| Vydáno v: | Schizophr Bull |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475908/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbx023.016 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|